Linear multilevel (mixed models) regression analysis was employed to assess viewing times and 2.5-SD-trimmed 'keep' or 'change' button-press data from the 'wanting' task, and attractiveness ratings from the 'liking' task. Main factors were drug, attractiveness and gaze direction. Control variables were session number, stimulus order, image set and OPRM1 group (AA or GA; see Supplementary Information).
'WANTING' TASK Both morphine and naltrexone decreased the average viewing time by~200 ms compared with placebo (main effect of drug, F (2,1208) = 3.6, P = 0.026). However, a planned contrast of keep button-press data revealed the expected pattern of 'wanting' increases with morphine and decreases with naltrexone for the most attractive female faces (M4N, t = 2.56, P = 0.011, Cohen's d = 0.95, Figure 1b ). Yet, for the least attractive females, morphine increased 'wanting' to change the photo, relative to placebo and naltrexone treatment (M4N, t = 2.52, P = 0.012, Cohen's d = 0.94). Analysis of total key-presses per image revealed a significant increase in 'wanting' behavior after morphine relative to naltrexone treatment (F (2,1206) = 5.2, P = 0.006, M4N, t = 3.18, P = 0.001, Cohen's d = 1.18), consistent with opioid mediation of human motivational preference for faces.
'LIKING' TASK In line with our prediction that the opioid system mediates 'liking' for the evolutionarily most valuable option, attractiveness ratings were significantly higher after morphine compared with naltrexone treatment only for the most attractive female faces (M4N, t = 2.13, P = 0.034, Cohen's d = 0.91, Figure 1b , data from 23 participants, see Supplementary Information). The main effect of drug did not reach significance (F (2,1314) = 1.8, P = 0.16).
Our results offer the first evidence that pharmacological manipulation of the human MOR system affects both aesthetic evaluation of and motivation for viewing opposite-sex faces. In line with findings from rodent literature, 13, 14 the effects of the MOR manipulations were strongest for the most valuable stimuli, that is, the most beautiful women. Morphine increased and naltrexone decreased men's 'liking' of these faces. We also observed an increase in 'wanting' behavior after morphine relative to naltrexone treatment, indicating that manipulation of the opioid system affected participants' motivation to expend effort. Specifically, activation of the opioid reward system with morphine not only increased 'wanting' key-press behavior to keep viewing the beautiful faces but also increased motivation to avoid viewing the least attractive faces.
The two components of reward, hedonic evaluation (´liking´) and motivational salience (´wanting´) were previously shown to partially dissociate when men viewed female faces of varying attractiveness levels, 6 and when males and females viewed images of infants. 15 The current study revealed an opioid-related increase in motivation to avoid the least attractive female faces, which was not mirrored by changes in reported attractiveness of these faces. For the most beautiful faces, however, the MOR manipulations affected 'liking' and 'wanting' similarly and in the expected directions. 11 Together, these findings suggest that the human opioid system may mediate social motivation by enhancing the salience and reward appraisal of the most valuable stimuli, while inhibiting 'wanting' of less valuable social cues.
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Owing to advances in high-throughput genomic technologies, it is becoming increasingly feasible to investigate the genetic architecture of these disorders at an unprecedented resolution. The challenge is how to make sense of the enormous flood of data generated by the diverse genomic studies that use these new Linkage statistics for 12 different phenotype-by-genotype models were calculated for a genome-wide panel of 6090 singlenucleotide polymorphisms (SNPs). For MD, data from the Genetics of Recurrent Early-Onset Major Depression (GenRED) collaborative are provided. 4 This included data on 418 microsatellite markers genotyped in 656 families consisting of 1494 all possible informative affective relative pairs. Data for genome-wide association studies (GWAS) were obtained from the psychiatric GWAS consortium. For BP, the sample included 7481 cases and 9250 controls, all of European ancestry, with data on ∼ 2.5 M genotyped and/or imputed SNPs. 5 Data on MD consisted of more than 1.2 million SNPs in 9240 cases and 9519 controls of recent European ancestry. 6 Gene expression data were obtained through a systematic review of studies on BP (n = 13) and MD (n = 7) using post-mortem brain tissue. Mega-analyses of the most comprehensive and rigorous of these studies were carried out using samples from all regions of the brain, the pre-frontal cortex and the hippocampus, where sufficient data were available. 7 Finally, Metamoodics includes a comprehensive meta-analysis of published candidate gene association studies of BP. Data on 33 polymorphisms in 18 genes reported on by three or more case-control studies were included in the meta-analysis. 8 A similar meta-analysis for MD is forthcoming. Schematic diagram showing in Figure 1 illustrates various resources and applications of Metamoodics.
Metamoodics includes a variety of online applications and tools for visualization and further analysis of the genomics data. Data visualization make use of NCBI SeqView API and a local mirror of the UCSC genome browser. The results can be queried by gene or chromosomal position to obtain either a gene level view via chromosomal or regional plots, or a more global view via the genome browser to investigate the genomic context of the findings. User-defined data can be uploaded to the genome browser using the custom-track option to visualize alongside the Metamoodics tracks. Analysis tools include SVAw 9 for surrogate variable analysis, METAw for meta-analysis and a gene expression package for individual and mega-analysis of expression data.
Metamoodics presents the latest results from genomic studies of mood disorders in a user-friendly web interface that enables users to rapidly compare findings from different experimental platforms across the genome, as well as drill down to specific findings to visualize how these relate to underlying genomic structure and function. Metamoodics provides the entire set of results of a given study rather than just significant ones, thus providing a complete and unbiased report of the findings. We will continue to update Metamoodics with findings from the latest genomic experiments of mood disorders, such as whole exome or genome sequencing and epigenetic studies. Metamoodics is a vital bioinformatics tool for investigating the genetic etiology of mood disorders that will only grow more powerful as new data are added.
Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis Brain-derived neurotrophic factor (BDNF) is a dimeric protein that has a central role in neurogenesis and neuroplasticity. This neurotrophin is found throughout the brain and is particularly abundant in the hippocampus and cerebral cortex, brain areas critical for the control of mood, emotion and cognition. 1 The secretion and uptake of BDNF in neurons occur at both axons and dendrites, either constitutively or in response to neural activity, and it is also synthesized and released by astrocytes.
2 It appears to be involved in the pathophysiology of mood disorders (MD) and schizophrenia (SZ), evidenced by reports of decreased serum and cerebrospinal fluid (CSF) levels in SZ, bipolar disorder (BD) and major depressive disorder (MDD). [3] [4] [5] Furthermore, BDNF levels are influenced by psychiatric medications such as antidepressants, mood stabilizers and antipsychotics. [3] [4] [5] On these grounds, BDNF levels as measured in serum and plasma have been promoted as a potential biomarker of diagnosis in these psychiatric disorders. 6 BDNF crosses the blood-brain barrier, and its levels in serum and plasma are highly correlated with BDNF levels in CSF (r = 0.8). 7, 8 Several studies have taken advantage of this 'window to the brain', with the great majority showing decreased BDNF levels in acutely ill subjects. However, the specificity, extent and relationship of peripheral BDNF levels to disease activity are not fully known; clarifying these issues was the aim of this metaanalysis. The hypothesis of this comparative meta-analysis was that peripheral BDNF levels would be lower in SZ and MD during acute episodes, and that serum or plasma BDNF could serve as a biomarker of disease activity, whereas not as a biomarker for diagnosis in these conditions.
To quantify and validate the specificity of serum and plasma BDNF levels in this study, we combined and compared results from a systematic and quantitative meta-analysis of electronic databases for MD and SZ. Inclusion criteria were studies that measured BDNF in plasma or serum in vivo in adult subjects with BD, MDD or SZ. Results from these studies were compiled to measure the effect size (ES) of BDNF level differences between patients and controls. To adjust for systematic measurement effects, we calculated the ES of each study according to Hedges' g from their means and s.d., which produces an unbiased ES adjusted for sample size. The direction of the ES was positive if patients showed increased BDNF, and negative if they showed decreased BDNF levels when compared with controls. As the data were highly skewed, we used non-parametric methods. KruskalWallis test and Conover-Inman post hoc test were used for statistical analysis. All tests were two-tailed, and we considered statistically significant P-values o 0.05. Results are shown as
